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Letter to the Editor 
 
Re: The"PROMIS"of Magnetic Resonance Imaging Cost 
Effectiveness in Prostate Cancer Diagnosis? Jochen Walz Eur 
Urol. 2017 Sep 28. pii: S0302-2838(17)30779-0. 
 
We would like to thank Dr. Walz for his editorial remarks on our paper on the 
health economic impact of introducing MRI in the prostate cancer pathway (1,2) 
and respond to the specific issues raised.   
  1. We agree that there is uncertainty in the results, but, on balance, the 
mpMRI first strategy is the most likely to be cost-effective, as the benefits of early 
diagnosis of more CS cancers outweigh the added costs of using mpMRI first.  
2. The accuracy of targeted biopsies is informed by a systematic review and 
meta-analysis published in this journal (3), that suggests that targeted biopsies 
are 20% more sensitive than the standard “PROMIS”-type biopsy. Moreover, the 
sensitivity analysis explored the impact of changes to the sensitivity of MRI-
targeted biopsy. If the increase in sensitivity of MRI-targeted biopsy compared to 
the standard “PROMIS” biopsy is below 15%, biopsy first strategies are cost-
effective.  
3. The cost-effectiveness analysis did not test the impact of reductions in the 
accuracy of MRI but it did explore changes in its cost (see Online Material p57-
62). The mpMRI strategy is cost-effective for increases in the cost of mpMRI up 
to 30%. Furthermore, the adoption of MRI as the foundation of the pathway will 
naturally lead to standardisation and QA procedures so that quality issues will 
become progressively less relevant.  
4. We agree that inappropriate use of mpMRI is an issue, but we believe that 
concerns about how mpMRI might be misused should not preclude its 
appropriate use to the benefit of patients.  
5. We believe that, although the CEA is in the UK setting, the relative ranking 
of the strategies is likely to be applicable to any developed health care system as 
long as the relative differences between the parameter inputs are similar (e.g. 
similar differences between the cost of mpMRI vs cost of biopsy, similar 
accuracy, etc.). 
The ‘cautious’ position being taken is not neutral in terms of its potential harm to 
patients. With the introduction of any piece of research to an existing canon 
there is always the opportunity to point to inevitable residual uncertainties and 
make the plea for ‘one more trial’.   Whilst the position of skepticism remains an 
important cornerstone of the scientific method, its continued and repeated 
adoption – in the face of mounting evidence that an intervention confers distinct 
benefits to patients in a cost-effective manner - can be a source of harm.  In the 
case of mpMRI and prostate cancer diagnosis the harms that might be conferred 
to patients and populations by delayed implementation include: over-diagnosis; 
missed diagnosis; unnecessary biopsy; poor risk-stratification; inappropriate 
treatment allocation and sub-optimal use of resource (4,5). In this particular 
case, each year of delay means that many men in Europe will have to 
contemplate a prostate biopsy that will be performed in a sub-optimal manner 
and incur costs that do not result in the most desirable outcomes.  
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